Compare Stocks

Date Range: 

 IQVIABitcoin GroupCharles River Laboratories InternationalExact SciencesIncyte
SymbolNYSE:IQVOTCMKTS:BTGGFNYSE:CRLNASDAQ:EXASNASDAQ:INCY
Price Information
Current Price$262.27$48.00$455.04$98.22$69.78
50-Day Moving Average$253.83$42.31$421.64$104.37$75.54
52-Week Low$146.00$25.63$205.97$71.86$68.82
52-Week High$265.34$69.50$458.27$159.54$101.47
MarketRank™
Overall Score2.00.92.12.52.9
Analysis Score2.50.02.44.43.2
Community Score4.74.34.35.05.0
Dividend Score0.00.00.00.00.0
Ownership Score1.70.02.52.53.3
Earnings & Valuation Score1.30.01.30.63.1
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyHold
Consensus Price Target$262.18N/A$399.83$151.06$91.29
% Upside from Price Target-0.04% downsideN/A-12.13% downside53.80% upside30.82% upside
Trade Information
Market Cap$50.25 billion$18.55 billion$22.93 billion$16.89 billion$15.41 billion
Beta1.420.261.141.290.76
Average Volume896,554386422,1781,541,3081,271,133
Sales & Book Value
Annual Revenue$11.36 billionN/A$2.92 billion$1.49 billion$2.67 billion
Price / Sales4.42N/A7.8411.325.78
Cashflow$13.17 per shareN/A$13.40 per share$1.49 per shareN/A
Price / Cash19.92N/A33.9665.70N/A
Book Value$32.76 per shareN/A$42.55 per share$18.77 per share$11.92 per share
Price / Book8.01N/A10.695.235.85
Profitability
Net Income$279 millionN/A$364.30 million$-848,530,000.00$-295,700,000.00
EPS$6.03N/A$8.13($1.38)($1.06)
Trailing P/E Ratio84.060.0058.64N/A45.91
Forward P/E Ratio27.9038.83N/A20.05
P/E Growth2.43N/A3.07N/A0.88
Net Margins4.69%N/A12.10%-50.52%12.41%
Return on Equity (ROE)23.95%N/A23.59%-8.93%15.77%
Return on Assets (ROA)6.03%N/A8.66%-4.86%11.66%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio2.11%N/A1.17%0.53%0.01%
Current Ratio1.05%N/A1.36%2.47%3.97%
Quick Ratio1.05%N/A1.15%2.34%3.94%
Ownership Information
Institutional Ownership Percentage87.01%N/A93.28%88.31%91.98%
Insider Ownership Percentage1.10%N/A1.20%1.40%15.80%
Miscellaneous
Employees70,0002718,4005,0001,773
Shares Outstanding191.61 million386.49 million50.40 million171.95 million220.84 million
Next Earnings Date10/19/2021 (Estimated)N/A11/4/2021 (Estimated)10/26/2021 (Estimated)11/4/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Expert Ratings For Incyte - Benzinga - BenzingaExpert Ratings For Incyte - Benzinga - Benzinga
benzinga.com - September 23 at 5:46 PM
Incyte on a Roll with Two FDA Wins in Two Days - BioSpaceIncyte on a Roll with Two FDA Wins in Two Days - BioSpace
biospace.com - September 23 at 5:46 PM
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America - Yahoo FinanceIncyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America - Yahoo Finance
finance.yahoo.com - September 23 at 5:46 PM
Incyte Corporation (INCY) Stock Declines -7.44% This Week; Should You Buy? - InvestorsObserverIncyte Corporation (INCY) Stock Declines -7.44% This Week; Should You Buy? - InvestorsObserver
investorsobserver.com - September 23 at 12:46 PM
Incyte : Stifel Adjusts Incytes Price Target to $85 from $93, Keeps Hold Rating - marketscreener.comIncyte : Stifel Adjusts Incyte's Price Target to $85 from $93, Keeps Hold Rating - marketscreener.com
marketscreener.com - September 23 at 12:46 PM
Incyte Corporation Provides Revenue Guidance for the Year 2022 - marketscreener.comIncyte Corporation Provides Revenue Guidance for the Year 2022 - marketscreener.com
marketscreener.com - September 23 at 12:46 PM
Incyte Sinks After Skin Cream Wins Approval With a Warning (1) - Bloomberg LawIncyte Sinks After Skin Cream Wins Approval With a Warning (1) - Bloomberg Law
news.bloomberglaw.com - September 23 at 12:46 PM
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America - Yahoo FinanceKnight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America - Yahoo Finance
finance.yahoo.com - September 23 at 12:46 PM
Incyte and Knight Therapeutics ink exclusive supply and distribution agreement - Seeking AlphaIncyte and Knight Therapeutics ink exclusive supply and distribution agreement - Seeking Alpha
seekingalpha.com - September 23 at 12:46 PM
On a JAK roll, Incyte wins FDA green light to expand Jakafi in chronic graft-versus-host disease - FiercePharmaOn a JAK roll, Incyte wins FDA green light to expand Jakafi in chronic graft-versus-host disease - FiercePharma
fiercepharma.com - September 23 at 12:46 PM
Morgan Stanley Cuts Incyte (NASDAQ:INCY) Price Target to $80.00Morgan Stanley Cuts Incyte (NASDAQ:INCY) Price Target to $80.00
americanbankingnews.com - September 23 at 11:04 AM
Incyte (NASDAQ:INCY) PT Lowered to $86.00Incyte (NASDAQ:INCY) PT Lowered to $86.00
americanbankingnews.com - September 23 at 9:38 AM
Incyte (NASDAQ:INCY) PT Lowered to $80.00 at Morgan StanleyIncyte (NASDAQ:INCY) PT Lowered to $80.00 at Morgan Stanley
marketbeat.com - September 23 at 9:20 AM
Incyte (NASDAQ:INCY) Lowered to Market Perform at SVB LeerinkIncyte (NASDAQ:INCY) Lowered to Market Perform at SVB Leerink
americanbankingnews.com - September 23 at 9:02 AM
Inctyes ruxolitinib scores its second approval in two days, this time in chronic graft-versus-host disease - Endpoints NewsInctye's ruxolitinib scores its second approval in two days, this time in chronic graft-versus-host disease - Endpoints News
endpts.com - September 23 at 7:35 AM
Incyte : SEC Charges Former Executive With Insider Trading On A Misappropriation Theory—With A Twist - marketscreener.comIncyte : SEC Charges Former Executive With Insider Trading On A Misappropriation Theory—With A Twist - marketscreener.com
marketscreener.com - September 23 at 7:35 AM
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America - GlobeNewswireKnight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America - GlobeNewswire
globenewswire.com - September 23 at 7:35 AM
Incyte (NASDAQ:INCY) Sets New 12-Month Low at $69.42Incyte (NASDAQ:INCY) Sets New 12-Month Low at $69.42
americanbankingnews.com - September 23 at 2:16 AM
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) - Business WireIncyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) - Business Wire
businesswire.com - September 22 at 10:55 PM
Incyte Announces FDA Of Jakafi For Treatment Of Chronic Graft-Versus-Host Diseases - BenzingaIncyte Announces FDA Of Jakafi For Treatment Of Chronic Graft-Versus-Host Diseases - Benzinga
benzinga.com - September 22 at 5:55 PM
Recon: FDA approves Incytes eczema cream with boxed warnings; Biden pledges 500M doses of Pfizer vaccine - Regulatory FocusRecon: FDA approves Incyte's eczema cream with boxed warnings; Biden pledges 500M doses of Pfizer vaccine - Regulatory Focus
raps.org - September 22 at 5:55 PM
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) - Maryville Daily TimesIncyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) - Maryville Daily Times
thedailytimes.com - September 22 at 5:55 PM
Incyte eczema drug wins FDA OK, but with safety warning - BioPharma DiveIncyte eczema drug wins FDA OK, but with safety warning - BioPharma Dive
biopharmadive.com - September 22 at 5:55 PM
Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHDBack To Back FDA Approval For Incyte - This Time For Jakafi In GVHD
benzinga.com - September 22 at 2:07 PM
FDA approves Incytes Jakafi in chronic graft-versus-host disease indicationFDA approves Incyte's Jakafi in chronic graft-versus-host disease indication
seekingalpha.com - September 22 at 1:46 PM
FDA approves Incytes Jakafi in chronic graft-versus-host disease indication - Seeking AlphaFDA approves Incyte's Jakafi in chronic graft-versus-host disease indication - Seeking Alpha
seekingalpha.com - September 22 at 12:54 PM
Incyte (NASDAQ:INCY) Rating Lowered to C+ at TheStreetIncyte (NASDAQ:INCY) Rating Lowered to C+ at TheStreet
marketbeat.com - August 24 at 7:13 AM
3 S&P 500 Laggards Ready to Run3 S&P 500 Laggards Ready to Run
marketbeat.com - July 29 at 10:40 AM
DateCompanyBrokerageAction
9/23/2021IncyteMorgan Stanley
Lower Price Target
9/23/2021IncyteRoyal Bank of Canada
Lower Price Target
9/10/2021IQVIAArgus
Boost Price Target
8/23/2021Charles River Laboratories InternationalArgus
Boost Price Target
8/17/2021Charles River Laboratories InternationalUBS Group
Boost Price Target
8/5/2021Charles River Laboratories InternationalCredit Suisse Group
Boost Price Target
8/5/2021Charles River Laboratories InternationalWells Fargo & Company
Boost Price Target
8/5/2021Charles River Laboratories InternationalRobert W. Baird
Boost Price Target
8/4/2021IncyteSVB Leerink
Lower Price Target
7/29/2021Exact SciencesStifel Nicolaus
Lower Price Target
7/29/2021Exact SciencesBTIG Research
Lower Price Target
7/29/2021Exact SciencesCanaccord Genuity
Lower Price Target
7/29/2021Exact SciencesOppenheimer
Lower Price Target
7/29/2021Exact SciencesRobert W. Baird
Lower Price Target
7/28/2021IQVIAMorgan Stanley
Boost Price Target
7/28/2021IQVIAMizuho
Boost Price Target
7/28/2021IQVIAPiper Sandler
Boost Price Target
7/28/2021IQVIADeutsche Bank Aktiengesellschaft
Boost Price Target
7/28/2021IQVIACitigroup
Boost Price Target
7/28/2021IQVIARobert W. Baird
Boost Price Target
7/20/2021IQVIACredit Suisse Group
Boost Price Target
7/20/2021Charles River Laboratories InternationalCredit Suisse Group
Boost Price Target
7/20/2021IncyteBenchmark
Upgrade
7/14/2021Exact SciencesSVB Leerink
Lower Price Target
7/13/2021IQVIABarclays
Boost Price Target
6/25/2021IncyteRoyal Bank of Canada
Lower Price Target
6/21/2021Exact SciencesWells Fargo & Company
Boost Price Target
6/15/2021Exact SciencesRaymond James
Initiated Coverage
6/15/2021IncyteWilliam Blair
Reiterated Rating
6/15/2021IncyteSVB Leerink
Reiterated Rating
6/3/2021Exact SciencesThe Goldman Sachs Group
Initiated Coverage
5/31/2021Charles River Laboratories InternationalRobert W. Baird
Reiterated Rating
5/28/2021Charles River Laboratories InternationalCredit Suisse Group
Boost Price Target
5/28/2021Charles River Laboratories InternationalJPMorgan Chase & Co.
Boost Price Target
5/28/2021Charles River Laboratories InternationalCitigroup
Boost Price Target
5/25/2021Charles River Laboratories InternationalTruist Securities
Boost Price Target
5/25/2021Exact SciencesWells Fargo & Company
Initiated Coverage
5/14/2021IQVIAKeyCorp
Boost Price Target
5/14/2021Charles River Laboratories InternationalKeyCorp
Boost Price Target
5/12/2021IQVIACanaccord Genuity
Boost Price Target
5/12/2021IQVIAArgus
Boost Price Target
5/12/2021Exact SciencesTruist
Lower Price Target
5/12/2021Exact SciencesTruist Securities
Lower Price Target
5/5/2021Charles River Laboratories InternationalDeutsche Bank Aktiengesellschaft
Boost Price Target
5/5/2021Charles River Laboratories InternationalRobert W. Baird
Boost Price Target
5/5/2021Exact SciencesCraig Hallum
Lower Price Target
5/5/2021Exact SciencesBTIG Research
Lower Price Target
5/5/2021Exact SciencesSVB Leerink
Lower Price Target
5/5/2021IncyteMorgan Stanley
Lower Price Target
4/26/2021IQVIATruist
Boost Price Target
4/26/2021IQVIATruist Securities
Boost Price Target
4/26/2021IQVIAMorgan Stanley
Boost Price Target
4/26/2021IQVIABarclays
Boost Price Target
4/23/2021IQVIACitigroup
Boost Price Target
4/23/2021IQVIAJefferies Financial Group
Boost Price Target
4/23/2021IQVIARobert W. Baird
Boost Price Target
4/23/2021IQVIADeutsche Bank Aktiengesellschaft
Boost Price Target
4/23/2021IQVIAMizuho
Boost Price Target
4/16/2021IQVIAStephens
Upgrade
4/9/2021IQVIAMizuho
Boost Price Target
4/5/2021IncyteMorgan Stanley
Lower Price Target
3/15/2021IQVIAKeyCorp
Upgrade
3/8/2021IQVIABarclays
Initiated Coverage
2/25/2021Charles River Laboratories InternationalMorgan Stanley
Boost Price Target
2/18/2021Charles River Laboratories InternationalTruist
Boost Price Target
2/18/2021Charles River Laboratories InternationalCredit Suisse Group
Boost Price Target
2/18/2021Charles River Laboratories InternationalDeutsche Bank Aktiengesellschaft
Boost Price Target
2/18/2021Exact SciencesRobert W. Baird
Lower Price Target
2/17/2021Exact SciencesStifel Nicolaus
Boost Price Target
2/17/2021Exact SciencesSVB Leerink
Boost Price Target
2/17/2021Exact SciencesCowen
Boost Price Target
2/10/2021IncyteMorgan Stanley
Lower Price Target
2/10/2021IncyteSVB Leerink
Downgrade
1/27/2021Exact SciencesTruist
Initiated Coverage
1/21/2021Exact SciencesSVB Leerink
Boost Price Target
1/12/2021Exact SciencesCanaccord Genuity
Boost Price Target
1/7/2021IncyteTruist
Initiated Coverage
1/4/2021IncyteGuggenheim
Upgrade
12/22/2020Charles River Laboratories InternationalArgus
Boost Price Target
12/16/2020Charles River Laboratories InternationalSmith Barney Citigroup
Downgrade
11/24/2020Charles River Laboratories InternationalKeyCorp
Boost Price Target
11/9/2020IncyteMorgan Stanley
Lower Price Target
11/6/2020IncyteBMO Capital Markets
Lower Price Target
11/6/2020IncyteRoyal Bank of Canada
Lower Price Target
11/3/2020Charles River Laboratories InternationalTruist
Boost Price Target
10/30/2020Charles River Laboratories InternationalMorgan Stanley
Boost Price Target
10/30/2020Charles River Laboratories InternationalDeutsche Bank Aktiengesellschaft
Boost Price Target
10/29/2020Exact SciencesUBS Group
Downgrade
10/28/2020Exact SciencesCanaccord Genuity
Boost Price Target
10/28/2020Exact SciencesOppenheimer
Boost Price Target
10/15/2020IncyteBank of America
Lower Price Target
10/13/2020IncyteMorgan Stanley
Boost Price Target
9/14/2020Charles River Laboratories InternationalArgus
Boost Price Target
8/9/2020IncyteCowen
Reiterated Rating
8/6/2020IncyteBMO Capital Markets
Boost Price Target
8/6/2020IncyteCredit Suisse Group
Lower Price Target
8/6/2020IncyteMorgan Stanley
Boost Price Target
8/4/2020IncyteMizuho
Initiated Coverage
8/4/2020IncyteSVB Leerink
Boost Price Target
8/3/2020IncyteRoyal Bank of Canada
Boost Price Target
11/30/2018Bitcoin GroupJefferies Financial Group
Downgrade
11/26/2018Bitcoin GroupStifel Nicolaus
Reiterated Rating
(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.